Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: A prospective, randomized trial

Pancreatology

Volumn 14, Issue 4, 2014, Pages 263-267

  Park, Ji Young ^a   Jeon, Tae Joo ^a   Hwang, Mi Won ^a   Sinn, Dong Hyun ^a   Oh, Tae Hoon ^a   Shin, Won Chang ^a   Choi, Won Choong ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Endoscopic retrograde cholangiopancreatography; Nafamostat; Pancreatitis; Post endoscopic retrograde cholangiopancreatography complications; Post endoscopic retrograde cholangiopancreatography pancreatitis; Ulinastatin

Indexed keywords

NAFAMSTAT; NAFAMSTAT MESILATE; PLACEBO; ULINASTATIN; ULISTIN; UNCLASSIFIED DRUG; GLYCOPROTEIN; GUANIDINE DERIVATIVE; PROTEINASE INHIBITOR;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOSCOPE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HYPERAMYLASEMIA; HYPERLIPASEMIA; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ADVERSE EFFECTS; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

ADULT; AGED; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; GLYCOPROTEINS; GUANIDINES; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS;

EID: 84905080043     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2014.03.022     Document Type: Article

References (22)

1. K.S. Yoo, K.R. Huh, Y.J. Kim, K.O. Kim, C.H. Park, and T. Hahn et al. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial Pancreas 40 2011 181 186
2. J.H. Chang, I.S. Lee, H.K. Kim, Y.K. Cho, J.M. Park, and S.W. Kim et al. Nafamostat for prophylaxis against post-endoscopic retrograde cholangiopancreatography pancreatitis compared with gabexate Gut Liver 3 2009 205 210
3. Y.W. Yoo, S.W. Cha, A. Kim, S.Y. Na, Y.W. Lee, and S.H. Kim et al. The use of gabexate mesylate and ulinastatin for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis Gut Liver 6 2012 256 261
4. T. Ueki, K. Otani, K. Kawamoto, A. Shimizu, N. Fujimura, and S. Sakaguchi et al. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial J Gastroenterol 42 2007 161 167 (Pubitemid 46404221)
5. J.W. Yoo, J.K. Ryu, S.H. Lee, S.M. Woo, J.K. Park, and W.J. Yoon et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial Pancreas 37 2008 366 370
6. O. Oiofinlade Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography Gastroenterology 126 2004 632; author reply 632
7. R. Sotoudehmanesh, M. Khatibian, S. Kolahdoozan, S. Ainechi, R. Malboosbaf, and M. Nouraie Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP Am J Gastroenterol 102 2007 978 983 (Pubitemid 46698240)
8. A. Andriulli, G. Leandro, T. Federici, A. Ippolito, R. Forlano, and A. Iacobellis et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis Gastrointest Endosc 65 2007 624 632 (Pubitemid 46442832)
9. S. Chen, H. Shi, X. Zou, and H. Luo Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the emperor's new clothes or aladdin's magic lamp? Pancreas 39 2010 1231 1237
10. H. Fujishiro, K. Adachi, T. Imaoka, T. Hashimoto, N. Kohge, and N. Moriyama et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study J Gastroenterol Hepatol 21 2006 1065 1069 (Pubitemid 43823296)
11. T. Seta, and Y. Noguchi Protease inhibitors for preventing complications associated with ERCP: an updated meta-analysis Gastrointest Endosc 73 2011 700-706.e2
12. C.C. Chen, S.S. Wang, and F.Y. Lee Action of antiproteases on the inflammatory response in acute pancreatitis JOP 8 2007 488 494
13. C.W. Choi, D.H. Kang, G.H. Kim, J.S. Eum, S.M. Lee, and G.A. Song et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis Gastrointest Endosc 69 2009 e11 e18
14. P. Wang, Z.S. Li, F. Liu, X. Ren, N.H. Lu, and Z.N. Fan et al. Risk factors for ERCP-related complications: a prospective multicenter study Am J Gastroenterol 104 2009 31 40
15. T. Tsujino, T. Kawabe, and M. Omata Antiproteases in preventing post-ERCP acute pancreatitis JOP 8 2007 509 517 (Pubitemid 47263693)
16. T. Tsujino, Y. Komatsu, H. Isayama, K. Hirano, N. Sasahira, and N. Yamamoto et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial Clin Gastroenterol Hepatol 3 2005 376 383 (Pubitemid 40488346)
17. T. Keck Site-specific therapeutic effects of protease inhibitors: effect of route of administration in experimental pancreatitis Pancreatology 1 2001 656 661 (Pubitemid 33674963)
18. T. Keck, J.H. Balcom, B.A. Antoniu, K. Lewandrowski, A.L. Warshaw, and C.F. Fernandez-del Castillo Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis Surgery 130 2001 175 181 (Pubitemid 32721666)
19. K.T. Park, D.H. Kang, C.W. Choi, M. Cho, S.B. Park, and H.W. Kim et al. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? Pancreas 40 2011 1215 1219
20. E. Masci, G. Toti, A. Mariani, S. Curioni, A. Lomazzi, and M. Dinelli et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study Am J Gastroenterol 96 2001 417 423
21. M.E. Feurer, and D.G. Adler Post-ERCP pancreatitis: review of current preventive strategies Curr Opin Gastroenterol 28 2012 280 286
22. M.L. Freeman, J.A. DiSario, D.B. Nelson, M.B. Fennerty, J.G. Lee, and D.J. Bjorkman et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study Gastrointest Endosc 54 2001 425 434 (Pubitemid 33661145)